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1. Introduction  
 
1.1. Chronic Lymphocytic Leukemia 
 
1.1.1. Definition and Epidemiology 
 
Chronic lymphocytic leukemia (CLL), the most prevalent adult form of
 
leukemia in Western 
countries, is characterized by the clonal
 
proliferation and accumulation of neoplastic B 
lymphocytes in
 
the blood, bone marrow, lymph nodes, liver and spleen. The median
 
age of 
patients at diagnosis is 72 years, with only 10 to 15
 
percent under 50 years of age (Civil 
Rozman et al. 1995). The risk of developing CLL increases progressively with age without 
plateauing and is 2.8 times higher for older men than for older women.  
Since decades the clinical staging systems designed by Rai et al. and Binet et al. are the most 
useful methods for predicting survival in CLL ( Rai et al. 1975; Binet et al. 1981). 
  
1.1.2. Pathogenesis 
 
CLL was considered to be a homogeneous disease of immature, immune-incompetent, 
minimally self-renewing B cells, which accumulate relentlessly because of faulty apoptotic 
mechanisms. But these views have been changed in the past decade. Now CLL is a clinically 
heterogeneous disease originating from B lymphocytes that may differ in activation, 
maturation state, or cellular subgroup. Whereas CLL in historical view is a disease derived 
from naive B lymphocytes, CLL in current view is a disease derived from antigen-experienced 
B lymphocytes that differ in the level of immunoglobulin V-gene (IgVH) mutations (Nicholas 
Chiorazzi et al, 2005). 
 
The exact cause of CLL is not known. Anyway, CLL is characterized by clonal proliferation of 
mature, small but not-functional B lymphocytes in bone and blood. It can be assumed that 
genetic somatic changes play a decisive role. 
 
Chromosomal aberrations are detected in 40 to 50% of CLL cases by conventional 
cytogenetics and approximately half of the patients show single abnormalities.  
Chromosomal aberrations in CLL are important independent predictors of disease 
progression and survival. The most frequent genetic abnormalities are deletions in 13q (55%) 
and 11q (18%), trisomy 12 (16%), and deletions in 6q (6%). Five categories are defined with a 
statistical model: 17p deletion, 11q deletion, trisomy 12, normal karyotype, and 13q deletion 
as single abnormality; the median survival times for patients in these groups were 32, 79, 
114, 111 and 133 months. Deletion of 17p and an increased number of deletions at diagnosis 
were significantly associated with a shorter survival. And patients in the 17p- and 11q-
deletion groups had more advanced disease than those in the other three groups. Patients 
with 17p deletions had the shortest median treatment-free interval (9 months), and those 
with 13q deletions had the longest (92 months). In multivariate analysis, the presence or 
absence of a 17p deletion, the presence or absence of an 11q deletion, age, Binet stage, the 
serum lactate dehydrogenase level (LDH), and the white-cell count gave significant 
prognostic information in advanced CLL stages (Sivia Bea et al. 2002; Hartmut Döhner et al. 
2000). 
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1.1.3. Clinical Presentations 
 
As with other lymphomas, there is not a reliable symptom of chronic lymphocytic leukemia. 
In the early stages of CLL the disease is usually asymptomatic. The most common symptom is 
the appearance of enlarged lymph nodes. In the advanced stage patients suffer from reduced 
performance state, B-symptoms and infections. 
 
CLL is often discovered by accident during a blood test as part of the diagnosis of other 
diseases. The following symptoms occur during the course of the illness: lymph node swelling, 
liver enlargement, spleen enlargement, skin symptoms such as pale skin and mucous, 
pruritus, eczema, mycoses, herpes zoster, skin bleeding, knotty infiltrates, parotid, 
leukocytosis with lymphocytosis >10,000/ μl, high percentage in the bone marrow of mature 
lymphocytes, and antibody deficiency syndrome by replacing the normal B-cells. 
 
Infections are the major cause of morbidity and mortality in patients with CLL. Predisposition 
to infection in CLL is mediated through various abnormalities including the immune defects 
inherent in the primary disease (impairment in humeral and cellular immunity) and the 
additional immunosuppression related to the therapeutic management of CLL. 
Hypogammaglobulinemia is probably the most important immune defect in terms of risk of 
severe bacterial infections, its frequency and severity progressing with the duration of the 
disease (Morra et al. 1999). 
 
 
1.1.4. Disease-specific Complications 
 
The majority of disease-specific complications in CLL are infections and autoimmune 
phenomena, based on the dysfunction of immunity. Both cellular and humeral immunity are 
impaired with qualitative and quantitative defects in B cells, T cells, NK cells, neutrophils and 
the monocyte/macrophage lineage. In fact, all patients have reduced immunoglobulin levels, 
even in early stages, and this might explain an association with an increased frequency and 
severity of infection (Dearden C. 2008).  
 
1.1.4.1. Impaired Immunity 
Patients with CLL show the dysregulated immune system, such as T- and B-cell dysfunction, 
hypogammaglobulinemia and autoimmune complications.  
There is increasing evidence of T-cell dysfunction in chronic lymphocytic leukemia which may 
contribute to the etiology and progress of the disease. An absolute CD8+ lymphocytosis 
correlates with disease progression and low expression of CD4 and CD8 (as found in 
autoimmune disease) is seen with abnormal expression of other surface molecules.  
(Scrivener S. et al 2002). 
 
T-cell dysfunction 
Through many studies, we know that decreased T-cell responses to mitogenic and T-cell 
dysfunction have been described in patients with CLL (Scrivener et al 2003; Scrivener et al 
2001). But the exact cellular and molecular mechanisms are still unclear (Wang et al. 2004).  
In untreated CLL, absolute T-cell numbers are either normal (Briggs et al. 1990) or more 
usually increased (Kimby et al. 1989), but there are deficient T-helper function and increased 
T-suppressor activity with a reversal of the CD4/CD8 ratio and a dominant Th2 response. 
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The T-cell dysfunction has significant abnormalities of expression of the many antigens and 
ligands necessary for production of immunoglobulin in CLL. 
Human CD4+CD25+ T-cells contain cells that suppress antigen-specific T-cell immune 
responses. In murine models, regulatory T cells (Treg cells) prevent autoimmune and 
inflammatory disease and inhibit antitumor immune responses. Most surprisingly, in the 
majority of patients with CLL treated with fludarabine-containing therapy regimens the 
inhibitory function of Treg cells was decreased or even abrogated. In addition, frequencies of 
Treg cells were significantly decreased after therapy with fludarabine (Beyer et al. 2005). 
 
Hypogammaglobulinemia 
During the course of CLL, reduction of normal immunoglobulins (Ig) levels is observed in 
most patients with CLL. All classes (IgG, IgA, and IgM) are affected. Furthermore, the severity 
tends to increase with the duration, stage and progress of the CLL. About 70% of patients 
with CLL have developed hypogammaglobulinemia within 7 years from diagnosis. 
 
 
1.1.4.2. Autoimmune Complications 
Autoimmune complications in patients with CLL are well known. The autoimmune hemolytic 
anemia (AIHA) is the most common autoimmune complication, followed by the autoimmune 
thrombocytopenia (AITP). AIHA may occur in 10% to 25% of patients with CLL during the 
course of their disease, and AITP may occur in 1% to 2%. Rarely, pure red cell aplasia (PRCA) 
has been encountered. These manifestations may occur even when the CLL is otherwise 
latent (Ward JH. 2001). Indeed, CLL is known as the most common cause of all AIHA. 
 
 
1.1.4.2.1. Autoimmune hemolytic anemia (AIHA)  
As mentioned above, AIHA is the most common autoimmune complication and CLL itself is 
the most common cause of AIHA. Therefore, AIHA may occur in asymptomatic untreated 
patients as well. Hamblin et al reported that AIHA was less frequently observed in non-
progressive Binet stage A (2.9%; p <0.02) than in other stages (13.3%) (Hamblin et al. 1986). 
And De Rossi G et al showed that CLL patients with AIHA and AITP represent a poor prognosis 
(De Rossi G et al. 1988). Therefore, the National Cancer Institute (NCI)-Sponsored Working 
Group Guidelines for CLL included AIHA among CLL-related signs of active disease. 
AIHA may be triggered by fludarabine, one of the most widely used and effective 
chemotherapeutic agents for CLL, and AIHA associated with Fludarabine may be difficult to 
treat and is often life-threatening. Beyer et al showed the influence of fludarabine-containing 
therapy regimens on autoimmune diseases in his study. He assessed 73 patients with B-cell 
chronic Lymphocytic leukemia (CLL) and 42 healthy controls. Through his study he found that 
in the majority of patients with CLL treated with fludarabine-containing therapy regimens the 
inhibitory function of Treg cells was decreased. In addition, frequencies of Treg cells were 
significantly decreased after therapy with fludarabine (Beyer et al. 2005). As we know, 
human CD4+CD25+ T cell contain cells that suppress antigen-specific T-cell immune 
responses. These naturally occurring regulatory CD4+CD25+ T cells (Treg cells) play a central 
role in the maintenance of peripheral tolerance by suppression of autoreactive T-cell 
populations. Decrease of these Treg cells was found in patients with autoimmune diseases 
(Shevach EM. 2000). 
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1.1.4.2.2. Autoimmune thrombocytopenia (AITP)  
Autoimmune thrombocytopenia (AITP), a condition of low platelets, can occur from primary 
causes, often referred to as idiopathic thrombocytopenic purpura (ITP), or secondary to an 
underlying disease, such as an autoimmune disorder or an infection. Secondary AITP can also 
occur with lymphoproliferative malignancies, such as chronic lymphocytic leukemia (CLL), 
Hodgkin's disease (HD), and non-Hodgkin's lymphomas (NHL). AITP associated with 
lymphoproliferative disorders has the same mechanism of platelet destruction as in 
idiopathic or primary AITP. The current treatment paradigm for secondary ITP varies 
according to the underlying condition. Standard treatments for primary AITP, which include 
corticosteroids, intravenous immunoglobulin (IVIG), anti-D, and splenectomy, are often 
successful in secondary AITP. However, in most situations with secondary AITP, treatment 
should focus on resolving the underlying disorder before treating the shortage of platelets, 
and, in the circumstances of AITP developing in patients with lymphoproliferative disorders, 
responses are frequently linked to remission of the primary malignancy (Liebman HA. 2009).                                   
 
 
1.1.4.3. Infections 
Infections frequently occur during course of CLL. The pathogenesis of infections in CLL is 
associated with cellular and humoral immune dysfunction, like hypogammaglobulinemia and 
the immunosuppressive effects of chemotherapy for CLL. It is also well-known that immune 
dysfunction and hypogammaglobulinemia are the main complications of CLL.  
Many therapies used to treat CLL, particularly purine analogues and alemtuzumab, are 
cytotoxic to T cells. This unintended effect of CLL therapy places patients at risk of 
opportunistic infections (e.g. pneumocystis carinii, cryptococcus, aspergillus) and 
reactivation of latent viral infection (CMV, VZV). In addition, other studies suggest that purine 
analogues also reduce the number and function of regulatory T cells that suppress antigen 
specific immune responses, illustrating the complex effects of therapy on the T cell 
compartment of CLL patients (Beyer et al. 2005). 
 
 
1.1.5. Diagnostic  
A National Cancer Institute-sponsored Working Group (NCI-WG) on CLL published guidelines 
for the design and conduct of clinical trials for patients with CLL in 1988, which were updated 
in 1996. Passing the past few decades, new prognostic markers, diagnostic parameters and 
new treatments have been achieved. Therefore, Hallek et al published updated guidelines for 
the diagnosis and treatment of CLL (Hallek et al. 2008). 
To diagnose CLL correctly, it is essential to evaluate the blood count, blood smear, and the 
immune phenotype of the circulating lymphoid cells. 
 
In the peripheral blood, the presence of at least 5 x 910  B lymphocytes/l is required for 
diagnosis of CLL. The clonality of the circulating B lymphocytes needs to be confirmed 
by flow cytometry, demonstrating a kappa or lambda light chain restriction. The 
immunophenotype of this lymphocyte population includes the co-expression of CD5 and 
CD19, as well as positivity for CD20, CD21, CD23, and CD24. Several variable 
immunophenotypic findings with prognostic importance include CD38 expression and 
intracellular expression of zeta-associated protein (ZAP70). Peripheral blood should be sent 
for cytogenetics and a fluorescence in situ hybridization (FISH) panel for common 
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chromosomal abnormalities (del [17p], del [11q22-23], del [13q14], and trisomy12) should 
be done in order to provide superior prognostic information (Abbott BL. 2006). 
 
The leukemia cells found in the blood smear are characteristically small, mature lymphocytes 
with a narrow border of cytoplasm and a dense nucleus lacking discernible nucleoli and 
having partially aggregated chromatic. These cells may be found admixed with larger or 
atypical cells, cleaved cells, or prolymphocytes, which may comprise up to 55% of the blood 
lymphocytes. Finding prolymphocytes in excess of this percentage would favor a diagnosis of 
prolymphocytic leukemia (B-cell PLL). Gumprecht nuclear shadows, or smudge cells, found as 
cell debris, are other characteristic morphologic features found in CLL (Hallek et al. 2008). 
 
Bone marrow finding in CLL includes normal to high cellularity with a B lymphocyte 
population that is monoclonal for kappa or lambda light chain expression as shown by 
immunohistochemistry.  
 
1.1.6. Staging 
                       
It is known that CLL has a variable course. Some patients after diagnosis survive for many 
years without therapy, while others might die within 1 year despite of aggressive therapy. 
For the assessment of prognosis of a patient with CLL either at the time of diagnosis or 
during the course of the disease, it was necessary to classify CLL in different stage. In 
addition, the staging systems now play an important role for planning therapy. 
 
Rai et al proposed a system for the clinical staging of CLL, which is based on Dameshek’s 
concept (Dameshek W. 1967) and had tested its validity in predicting survival in a 
retrospective as well as prospective follow-up study of a large number of patients. 
The following table 1 describes the staging system of CLL proposed by Rai et al. The 
prognostic factors are absolute lymphocytosis, bone marrow infiltration, lymphadenopathy, 
hepatomegaly, splenomegaly, anemia and thrombocytopenia.   
 
Table 1: Rai Staging of CLL (Rai et al. 1975)  
Stage Definition Median Survival 
 
Low risk 
  
> 10 years 
0 Absolute lymphocytosis > 15.000/μl  
 Bone marrow infiltration > 40%  
 
Intermediate risk 
 
7 years 
I 
 
Absolute lymphocytosis with lymphadenopathy  
II Absolute lymphocytosis with either hepatomegaly or 
splenomegaly (with or without lymphadenopathy) 
 
 
High risk 
 
2.3 – 5 years 
III 
 
 
Absolute lymphocytosis and anemia (Hb < 11g/dl) (with 
or without lymphadenopathy, hepatomegaly, or 
splenomegaly) 
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IV Absolute lymphocytosis and thrombocytopenia 
(<100.000/ 3mm ) with or without lymphadenopathy, 
hepatomegaly, splenomegaly, or anemia.  
 
 
Binet et al proposed a new classification in three prognostic groups. The prognostic factors in 
this staging system are as follows: anemia (Hb < 10 g/dl), thrombocytopenia (platelet count 
<100.000/ 3mm ), and the number of areas of lymphoid enlargement. In this system, 
thrombocytopenia and anemia appear as the most important risk factors. This three-stage 
classification only requires clinical examination and routine hematological analysis, and has a 
good prognostic value which was confirmed on the series of Montserrat and Rozman (Binet 
et al. 1981). 
The following table 2 describes the staging system of CLL proposed by Binet et al. 
 
Table 2: Binet Staging of CLL (Binet et al. 1981) 
Stage Definition Median Survival 
 
Low risk 
 
> 10 years 
A Hb ≥10 g/dl 
Platelet count normal 
Less than three areas of lymphoid enlargement 
(≥ 1cm)* 
 
 
Intermediate risk 
 
7 years 
B Hb ≥10 g/dl 
Platelet count normal 
Three or more areas of lymphoid enlargement 
(≥ 1cm)* 
 
 
High risk 
 
2.3 – 5 years 
C Hb < 10g/dl and/or  
Platelet count < 100.000/ 3mm  
Regardless of the number of areas of lymphoid 
enlargement (≥ 1cm)* 
 
* Lymphoid areas include cervical, axillary, inguinal unilateral or bilateral, liver, and spleen. 
 
In general, Binet staging system is commonly used in Europe, and Rai staging system in North 
America. Through these staging systems, we can see that there is a strong relationship 
between the stage of CLL and the prognosis; patients in earlier stages have long-term survival. 
However, there is a wide range of results even in patients within a given stage, and the stage 
alone does not precisely predict the prognosis for an individual patient, especially in patients 
at the early stages (Han T et al. 1984). 
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1.1.7. Prognostic Factors 
 
The individual prognosis of patients with CLL is extremely variable. The staging systems of 
CLL provide useful tools for predicting survival and planning therapy. Patients with low-risk 
disease (Rai stage 0, Binet stage A) have a median survival time of more than 10 years, those 
with intermediate-risk disease (Rai stage I or II, Binet stage B) have a median survival of 7 
years, and those with high-risk disease (Rai stage III or IV, Binet stage C) have a median 
survival of 2.3 – 5 years. For assigning these staging systems, we need to require only a 
physical examination and a blood count. Even though the staging systems are still very useful 
tools for assessing prognosis in patients with CLL, they have some limitations; for example, 
patients who will have a rapid progressive disease and those in whom the leukemia will run 
an indolent course are not identified. On the other hand, the majority of patients are 
currently diagnosed during routine medical examinations, when still asymptomatic. As a 
result, up to 80% of the patients have low-risk disease at diagnosis, thus limiting the 
prognostic value of clinical stages as a whole. Finally, the prognosis of a patient with CLL 
ultimately depends on complex relationships between the characteristics of the patient (age, 
gender, co-morbidity, performance status), the disease (burden, kinetics, genetics and 
biology of the tumor), as well as sensitivity of the disease to treatment. Staging systems are 
only one of the parameters in this complex interaction (Montserrat E. 2006). 
Montserrat showed in his study as well that a number of biological parameters, particularly 
serum markers, cytogenetics, IgVH mutational status, CD38 and ZAP-70 expression in 
leukemic cells, are important independent prognostic markers. ZAP-70 and IgVH mutations 
basically provide similar prognostic information and therefore they can substitute each other 
(Montserrat. 2006).   
 
Lymphocyte doubling time, serum levels of β2-microglobulin, thymidine kinase (Hallek et al. 
1996), soluble CD23 (Sarfati et al. 1996), as well as CD38 expression on malignant cells 
(Damle et al.1996) can help to predict disease activity and rapid progression, but the 
presence in the leukemic B cells of cytogenetic abnormalities like 11q or 17p deletions 
(Dohner et al. 2000), or somatic mutations in the immunoglobulin heavy chain genes (Damle 
et al. 1999; Hamblin et al. 1999) are better predictors of survival. A recent retrospective 
study from the French Cooperative Group on 146 patients for whom the Ig sequence could 
be obtained and with a long follow-up stressed the importance of the mutational profile of Ig 
genes in predicting the progression in Binet stage A patients. Stage A patients expressing 
mutated Ig genes have a 75% 12-year survival and a progression free survival of 156 months, 
as compared to a medium overall survival of 97 months and a progression free survival of 42 
months for patients with unmutated Ig genes.  
These results suggest that a high percentage of stage A patients requiring early treatment are 
included within this group. However, this study also showed that a small percentage of 
mutated cases (about 10%) may also require early treatment and may die from disease 
related causes (Vasconcellos et al. 2003). These data confirm the results of a monocentric 
German study which represents the greatest Binet stage A population so far with 189 
patients. The estimated median overall survival time of the group with IgVH homology of 98% 
or greater was 79 months, whereas the median OS was 152 months for the group with IgVH 
homology less than 98% (Kröber et al. 2002).  
 
A recent preliminary analysis performed on a common data base of the German and French 
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cooperative study groups identified short LDT and high sTK as the strongest predictors of 
rapid progression.  
 
 
1.1.8. Treatment Options  
 
CLL is an incurable disease. With chemotherapy, however, the prolongation of life and 
improvement of life’s quality can be achieved. 
 
Some patients in early stage of CLL (Rai stage 0, Binet stage A) survive for many years without 
therapy. Other patients in early stage need to be treated because of rapid progressive 
disease. A chemotherapy is generally recommended in patients with high-risk stage (Rai 
stage III/IV, Binet stage C) and in some patients with low-risk stage (Rai stage II, Binet stage A 
and B) according to the recommendation proposed by the Italian Society of Hematology (SIE) 
and two affiliates societies, the Italian Society of Experimental Hematology (SIES) and the 
Italian Group for Bone Marrow Transplantation (GITMO). They developed clinical practice 
guidelines for the therapy of CLL. The recommendations were developed through a 
systematic search of evidence and formulated according to explicit methods for consensus 
development. The indications for initiation of disease-specific therapy in CLL include the 
presence of at least one of these features: B symptoms (i.e. fever, sweats, extreme fatigue, or 
weight loss), progressive/obstructive lymphadenopathy or organomegaly, rapid lymphocyte 
doubling time, anemia or thrombocytopenia (of new onset, worsening or steroid-resistant) 
(Brugiatelli et al. 2006). 
 
With conventional chemotherapy CLL is incurable, making palliation of symptoms as well as 
prolongation of progression free survival and overall survival the goals of therapy. For many 
years alkylating agents, such as chlorambucil, with or without corticosteroids, have been the 
mainstay of treatment in CLL resulting in response rates of 40-77% among untreated patients. 
New therapeutic options arose by introduction of the purine analogues. Fludarabine has 
been most extensively investigated and showed marked activity with response rates between 
28-67% in relapsed patients and about 80% among untreated patients (Kalil et al. 2000; Rai 
et al. 2000). Further improvement may be achieved by combination therapies with 
fludarabine. In vitro studies revealed a synergistic activity of fludarabine with alkylating 
agents, such as cyclophosphamide (Bellosillo et al. 1999). Combination therapies with 
fludarabine and cyclophosphamide showed significant response rates between 80-100% 
(O’Brien et al. 1998; Flinn et al. 2000; Hallek et al. 2001) with CR rates between 35-50% in 
untreated patients. So far, the only treatment, which is able to prolong overall survival in CLL 
patients, is the combination of immunotherapy and chemotherapy, combining fludarabine, 
cyclophosphamide and rituiximab. The CLL8 trial of the German CLL Study Group 
demonstrated a significant better 3-year overall survival from 87% in comparison to 83% for 
patients treated with chemotherapy alone (Hallek et al 2010).  
 
 
Fludarabine (F) 
Fludarabine (Fludara®) is distributed in Germany by the company Bayer Schering Pharma. It 
is the best studied purine analogue used for the treatment of CLL. It is available in injection 
vials containing 50 mg dry substance. It is a fluorinated adenine (active ingredient: 
fludarabine-dihydrogen phosphate) and thus by definition an antimetabolite.  
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Concerning the FDA approval, fludarabine is indicated for the treatment of adult patients 
with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease 
has progressed during treatment with at least one standard alkylating-agent containing 
regimen. In Germany and more than 60 other countries fludarabine is also approved for first-
line treatment of CLL.  
The major side-effects are myelosuppression with neutropenia and immunosuppression and 
reduction of the T helper cells, at higher doses central nervous system (CNS) toxicity (rarely 
progressive encephalopathy (PML)), nausea, vomiting, mucositis/stomatitis, diarrhea, 
anorexia and elevation of transaminases (Adkins et al. 1997; Pott et al. 1997). 
 
Cyclophosphamide (C) 
Cyclophosphamide (Endoxan®, Cyclostin®) is distributed by the companies Pharmacia and 
Asta Medica, among others. It is available in injection vials containing 100 mg, 200 mg, 500 
mg and 1000 mg dry substance. The major side-effects are myelosuppression, nausea, 
vomiting (often delayed), allergic reactions, hair loss, mucositis/stomatitis, anorexia, 
cardiotoxicity (particularly at high doses), nephrotoxicity, hemorrhagic cystitis, neurotoxicity 
in the form of acute encephalopathy (with high-dose therapy), dermatotoxicity and rarely a 
syndrome of inappropriate ADH secretion. In diabetics, acute hypoglycemia may occur rarely.  
 
 
Combined Immunochemotherapy of CLL 
In recent years the development of monoclonal humanized antibodies such as rituximab 
(anti-CD20) and alemtuzumab (anti-CD52) has significantly increased the treatment options 
for CLL. In vitro studies have shown additional cytotoxic activity towards CD20 positive B 
cells when rituximab is combined with a number of different chemotherapeutic agents 
including purine analogues and alkylating agents. Four phase II studies explored the 
combination of fludarabine with rituximab or fludarabine plus cyclophosphamide with 
rituximab. Wierda et al conducted a study of rituximab in combination with fludarabine and 
cyclophosphamide in 135 previously untreated patients with advanced disease (stage Rai III 
or IV). Patients received six cycles of the triple combination. For the first cycle of treatment, 
rituximab was given at a dose of 375 mg/m² on day 1, and doses of cyclophosphamide and 
fludarabine at 250 and 25 mg/m² IV respectively on days 2 to 4. For the second and 
subsequent cycles, rituximab was given at doses of 500 mg/m² on day 1 and 
cyclophosphamide and fludarabine at the above doses were given on days 1 to 3. 76% of 
patients completed all six treatment cycles. In 79 pts evaluable so far, the ORR was 95% 
(75/79), of these 66% (52/79) were in CR, 14% (11/79) were in nodular PR and 15% (12/79) 
were in PR. Four percent did not respond and there was 1 early death. At 24 months, 61/63 
responders remained in CR or nodular PR (nPR). Molecular remission by PCR for IgVH 
mutations was documented in 59% (22/37) of a subset of patients studied. After a median 
follow up of 24 months, 93.7% (74/79) of patients survived. During the first infusion, fever 
and chills were experienced by nearly half the patients and infusion related symptoms 
(hypotension, nausea and dyspnea) occurred in 10% -18% of patients. These events were 
rare with subsequent infusions. Grade 4 neutropenia was seen in 20% of cycles administered, 
and grades 3 or 4 thrombocytopenia in 4%. Major infections (sepsis, pneumonia) were 
associated with 3% of cycles and minor infections (FUO, HSV, soft tissue) with 14% of cycles. 
Byrd et al compared in randomized phase II study fludarabine with concurrent versus 
sequential treatment with rituximab in symptomatic, untreated patients with CLL. The 
overall response rate with the concurrent regimen was 90% (47% CR) compared with 77% 
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(28% CR) with the sequential regimen (Byrd et al. 2003). 
Recently Keating et al reported the use of FCR combining fludarabine 25 mg/m² per day for 3 
days, cyclophosphamide 250 mg/m² per day for 3 days and rituximab 375 – 500 mg/m² on 
day 1 as initial therapy for 224 CLL patients with 70% CR, 10% nPR, 15% PR (ORR 95%, 
Keating et al. 2005). 
In the CLL4B study of the GCLLSG (Wendtner et al. 2004), patients with advanced CLL 
responding to initial chemotherapy with fludarabine alone or in combination with 
cyclophosphamide were randomized for treatment with alemtuzumab (CAMPATH-1H) in a 
dose of 30 mg i.v. TIW, 12 weeks or observation. Of 21 evaluable patients, 11 were 
randomized to alemtuzumab. At six months after randomization, two patients in the 
alemtuzumab arm converted to CR, while three patients in the observation arm progressed. 
After alemtuzumab treatment, five of six patients achieved a molecular remission in 
peripheral blood while all patients in the observation arm remained MRD positive. At 21.4 
months median follow-up, patients receiving alemtuzumab showed a significant longer 
progression free survival. Due to severe infections in seven of 11 patients in the 
alemtuzumab arm which were successfully treated the study was stopped. In conclusion, a 
consolidation therapy with alemtuzumab is able to achieve molecular remissions and longer 
survival in CLL, but a safe treatment regimen needs to be determined. 
The data described above show that when used in combination with a chemotherapy 
regimen containing fludarabine and cyclophosphamide, antibodies like alemtuzumab or 
rituximab are very effective agents for the treatment of CLL. The regimen of fludarabine plus 
cyclophosphamide (FC) and rituximab has shown so far the highest response rate in 
untreated patients to date, with molecular remissions in a large proportion of responding 
patients. The safety profile was as expected and manageable. This is in line with the 
superiority of rituximab plus chemotherapy combinations documented in follicular and 
aggressive NHL. 
At present there is no further information about the immunochemotherapy with fludarabine 
plus cyclophosphamide (FC) and rituximab in CLL patients with early disease (Binet A or 
asymptomatic B or Rai 0 or 1) and a high risk for disease progression. In these patients the 
achieving of molecular complete remissions should be the aim of treatment in order to 
prolong the progression free survival or the overall survival significantly. A randomized phase 
III trial of the German CLL study group treats stratified patients at high risk for disease 
progression with FCR versus observation (CLL7 protocol).  
 
However, despite the high remission rates achieved by fludarabine-based regimens, relapse 
of CLL after remission durations of months to several years is the rule. Therefore, additional 
treatment strategies aiming at eradication of the disease are currently being investigated.   
Hallek et al showed recently the better efficiency and good safety of the combination of FC 
with rituximab (FCR) in their study. They analyzed 817 first-line patients with CLL: 408 
patients were assigned to fludarabine, cyclophosphamide, and rituximab 
(chemoimmunotherapy group) and 409 to fludarabine and cyclophosphamide 
(chemotherapy group). At 3 years after randomization, 65% of patients in the 
chemoimmunotherapy group were free of progression compared with 45% in the 
chemotherapy group (hazard ratio 0·56 [95% CI 0·46—0·69], p<0·0001); 87% were alive 
versus 83%, respectively (0·67 [0·48—0·92]; p=0·01). Chemoimmunotherapy was more 
frequently associated with grade 3 and 4 neutropenia (136 [34%] of 404 vs. 83 [21%] of 396; 
p<0·0001) and leucocytopenia (97 [24%] vs. 48 [12%]; p<0·0001). Other side-effects, 
including severe infections, were not increased. There were eight (2%) treatment-related 
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deaths in the chemoimmunotherapy group compared with ten (3%) in the chemotherapy 
group (Hallek et al 2010). Therefore, the combination of FC with rituximab (FCR) is at present 
a new and promising treatment gold standard. 
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1.2. Rationale and Study Purpose of the CLL1-Protocol 
 
1.2.1. Rationale 
 
Two long-term French trials and a meta-analysis of most randomized trials demonstrated 
that therapy with chlorambucil, an oral alkylating agent and the standard treatment of CLL so 
far, could be deferred for Binet stage A patients. Moreover, deferring therapy until forced by 
disease progression does not compromise survival (CLL Trialists' Collaborative Group 1999, 
Dighiero et al. 1998).  
However, over 25 percent of these indolent cases, die of causes related to chronic 
lymphocytic leukemia, 40 percent progress to advanced stages, and 50 percent ultimately 
require treatment.  
The analysis of treatment requirement in this trial demonstrated that one third of patients 
included in the abstention arm required treatment before a 3-year follow-up (Dighiero et al. 
2002). 
Preliminary data of the CLL1 protocol of the GCLLSG on 182 patients showed that the 
cytogenetic abnormalities 17p-deletion and 11q-deletion, elevated serum thymidine kinase 
and a short lymphocyte doubling time (below 12 months) are independent prognostic factors 
with regard to progression free survival. Subsequently the next generation CLL7 trial used a 
combination of four prognostic factors (cytogenetics, s-TK, LDT, IgVH) to define patients at 
high risk for disease progression within Binet stage A patients.   
 
Although, presently available evidence favors the view that deferral of treatment for stage A 
patients, does not compromise their survival, these studies were conducted with alkylator-
based regimens (Dighiero et al. 1998). This recommendation may change, provided that new 
drugs demonstrated an advantage in CLL. In addition, these long term studies have shown 
that about one third of Rai stage 0 and Binet stage A patients die of CLL related causes. It is 
presently unclear whether young patients with Binet stage A whose leukemic B cells express 
unmutated V genes or deleterious chromosomal abnormalities like 11q deletions or 
alterations in the p53 protein or even mutated patients with a short doubling time or 
elevated levels of other prognostic indicators would benefit from early treatment. This 
possibility should therefore be tested in a prospective clinical trial.  
 
Until now there are no data available about the early use of purine analogues as single 
agents or in combination with alkylating agents like cyclophosphamide (FC) or antibodies 
(rituximab) as first-line therapy in Binet stage A patients.  
 
1.2.2. Purpose of the Study 
 
CLL is now increasingly diagnosed in younger patients and in the early stages, who represent 
a very inhomogeneous group regarding its illness and progression risk. It agrees that patient 
with smoldering CLL will not be treated. By using new prognostic parameters, a risk group 
among the remaining patients of stage A can be identified. Patients in a risk-group, in 
contrast to those in a low-risk group, tend to progress in higher stage (Binet stage B or C) 
within 12 months (Hallek et al. 1997). 
Based on the hypothesis that a good complete remission may result in prolongation of 
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disease-free interval and overall survival, it is objective of this study to examine whether an 
early treatment with fludarabine, currently the most effective therapeutic substance in CLL, 
would prevent or at least delay the progression of CLL in early stage.  
Through stratification, the initiation of the chemotherapy can be determined. Namely, the 
stratification can prevent the needless chemotherapy for patients with indolent CLL and 
make sure that only patients, who should receive chemotherapy within 2 years, would be 
treated (Hallek et al. 1997). 
 After randomized allocation, patients with high risk of progression are divided in two 
groups: the experimental arm "Early treatment with Fludarabine" and the standard arm 
"Watch and Wait". As endpoints, the quality of response, progression-free survival, overall 
survival and quality of life are evaluated. 
 
Through this study, we aim to analyze the influence of fludarabine in infections, impaired 
immunity and autoimmune disease by comparing the incidence of infections, 
hypogammaglobulinemia, AIHA and AITP in all three study arms. 
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2. Materials and Methods 
 
2.1. CLL-1 Protocol: Study Design 
 
 
Fig. 1:  CLL-1 study flow sheet 
 
It is a multi-center, risk-stratified, randomized phase III study on therapy with fludarabine of 
CLL in Binet stage A. The study has three different groups: The cohort I and II include patients 
with high risk of progression. Patients at high risk of progression are randomized between 
treatment (cohort I) and watch and wait (cohort II) according to a phase III protocol. In these 
two cohorts, the efficacy of treatment with fludarabine-chemotherapy versus watch and wait 
will be compared. 
The cohort III is an observation arm (watch and wait) in which all patients have low risk of 
progression. 
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It is very important to answer the following question:  
- Can the progression-free survival and the overall survival of CLL patients in Binet 
stage A by early, risk adapted therapy with fludarabine be extended? 
- What values have new prognostic factors in CLL patients in Binet stage A?  
     
 
2.1.1. Study on risk-adapted therapy of CLL in Binet stage A 
 
The risk of progression in patients in Binet stage A is assessed on the basis of bone marrow 
histology (infiltration type: non-nodular versus nodular), lymphocyte doubling time (LDT), 
serum thymidine kinase, and serum ß2-microglobulin. 
High risk of disease progression is defined as follows: 
  
 
 
Through the definition of high risk of disease progression, patients in Binet stage A can be 
divided in two groups: patients with high risk of progression and those without high risk of 
progression. In our study cohort I and cohort II belong to the group with high risk of 
progression, and cohort III belongs to the group with low risk of progression. 
As already mentioned, patients with high risk of progression are randomized between early 
treatment with fludarabine (cohort I) and “watch and wait” (cohort II). Therefore, only 
patients in cohort I receive the therapy with fludarabine. And patients in other two groups 
(cohort II and cohort III) are only observed and are treated only in case of progression 
according to the NCI-WG guidelines.  
 
2.1.1.1. Endpoints of the study. 
  Primary endpoint 
     - Progression-free survival  
   
  Secondary endpoints 
     - Overall survival 
     - Therapy efficacy (CR, PR, SD, Progression, remission duration) 
     - Occurrence of severe side effects caused by therapy with fludarabine. 
     - Occurrence of infections 
     - Quality of life  
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2.1.2. Assessment of the significance of new prognosis factors for CLL-patients in Binet 
stage A. 
For the analysis of prognostic factors, the following parameters are recorded in all patients 
at inclusion in the study: 
  ▪ Age 
 ▪ Gender 
 ▪ Binet stage 
 ▪ Rai stage 
 ▪ Lymphocyte count in peripheral blood 
 ▪ Hemoglobin 
 ▪ Platelet count 
 ▪ Bone marrow histology and cytology 
 ▪ Lymph node histology, when lymph node enlargement with at least 2cm diameter exists 
and aspiration with acceptable risk is possible (including assessment of the histological 
subtype of B-CLL and B-CLL with plasmacellular differentiation) (Harris et al. 1994) 
 ▪ Lymphocyte doubling time 
 ▪ Serum immunoglobulin level (IgA, IgM, IgG) 
 ▪ Serum-ß2-microglobulin 
 ▪ Serum thymidine kinase 
 ▪ Serum lactate dehydrogenase (LDH) 
 ▪ Serum albumin  
 ▪ Determination of the number of enlarged lymph nodes through clinical examination plus 
chest X-ray plus abdominal sonography 
 ▪ Splenomegaly (determined by sonography) 
 ▪ Hepatomegaly (determined by sonography) 
 ▪ Molecular cytogenetic using FISH (including detection of p53 alterations, 11q-deletion) 
 ▪ B-symptoms 
 ▪ ECOG performance status 
 
2.1.2.1. Endpoints for the analysis of prognostic factors 
Primary endpoint 
   - Progression-free survival 
 
Secondary endpoint 
    - Overall survival 
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2.2. Study Population 
 
2.2.1. Study Population 
Previously untreated male or female patients with Binet stage A CLL, as defined by NCI 
criteria (Cheson et al. 1996). 
 
2.2.2. Inclusion Criteria (Cheson et al. 1996) 
 1. Established diagnosis of B-CLL in Binet stage A. 
      The diagnostic criteria for B-CLL are: 
- Persistent (> 3 months) increase in absolute lymphocyte counts in the blood (> 
5000/μl) 
- More than 30% mature lymphocytes in the bone marrow of normal or increased 
cellularity 
- Immunophenotype confirmation of the diagnosis according to the following criteria: 
Low expression of surface immunoglobulin, CD5+, CD19+, CD20+, CD23+, and the 
double labeling of CD5/CD19 ( Matutes et al.1994, Rozman et al.1995) 
 2. First diagnosis within 3 years before inclusion in study 
 3. No prior treatment 
 4. Age between 18 and 75 years old 
 5. ECOG performance status 0-2 
 6. No insufficiency of important organ functions 
 7. Written informed consent for study participation  
 8. Existence of the parameters for risk stratification 
 9. Willingness to accept contraception if randomized to the treatment arm (cohort I) for the 
duration of therapy  
 
2.2.3. Exclusion Criteria (Cheson et al. 1996) 
 1. Age less than 18 years old and over 75 years old 
 2. ECOG performance status >2 
 3. Clinically apparent immune hemolysis 
 4. Positive Coombs test 
 5. Clinically apparent immune thrombocytopenia 
 6. Active secondary malignancy 
 7. Simultaneous presence of other neoplasia, and previous radiotherapy or chemotherapy 
for any neoplastic diseases. 
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 8. HIV-infection 
 9. Pregnancy and Lactation 
 10. Participation in another clinical trial before and during the study 
 11. The following concomitant diseases: 
- Clinical apparent heart insufficiency 
- Cardiomyopathy 
- Myocardial infarction within the past 6 months prior to the study 
- Severe chronic obstructive lung disease with hypoxemia 
- Severe diabetes mellitus 
- Hypertension difficult to control 
- Infection difficult to control 
- Impaired liver function with serum bilirubin > 2mg/dl and/or transaminase over 3 
times of the normal 
- Impaired renal function with creatinine > 3mg/dl 
- Clinically apparent cerebral dysfunction 
- Serious psychiatric or neurological diseases that would preclude participation in the 
required study procedures 
  
 
2.3. Treatment Schedule 
 
2.3.1. Procedures of risk stratification and randomization 
 
The first step following after the registration is the assessment of lymphocyte doubling time 
(LDT) by the study center; at least 4 blood lymphocyte counts are therefore needed. Bone 
marrow histology is also important to evaluate the infiltration. These two parameters, 
together with serum thymidine kinase and serum-ß2-microglobulin, would be used to 
perform risk stratification in order to determine whether the patients have high risk of 
progression or not. Patients stratified to the high risk group will furthermore be randomized 
between the treatment arm (cohort I) and the watch and wait arm (cohort II). (see chapter 
2.1.1.)  
 
2.3.2. Regimen 
 
The chemotherapy regimen of patients at high risk of disease progression, who were 
randomized to the therapy arm (Cohort I), is as follows: 
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Study medication will be given in at least 4 cycles, but not more than 6 cycles. The restaging 
is scheduled after 2 and 4 cycles of therapy. The number of treatment cycles follows the 
following guidelines: 
 
- Complete Remission (CR) after 2 cycles: Administration of 2 additional (total 4) 
cycles of fludarabine 
- Complete Remission (CR) first after 4 cycles: Administration of 2 additional (total 6) 
cycles of fludarabine. 
- Partial Remission (PR) after 4 cycles: Administration of additional (total 6) cycles of 
fludarabine 
- Progression after 2 or more cycles: Therapy stop 
- No change after 2 cycles: Administration of 2 additional cycles of fludarabine 
- No change after 4 cycles: Therapy stop 
 
2.3.3. Dose Modification 
 
At the following side effects, the dose of fludarabine in the next cycle should be reduced: 
 Occurrence of severe general infection after administration of chemotherapy in the 
phase of neutropenia: 75% 
 Severe neutropenia (if no severe neutropenia existed before the therapy): 
- Neutrophil nadir under 500/μl: 50%. 
- Neutrophil nadir under 1000/μl: 75%. 
 Severe thrombocytopenia (if no severe thrombocytopenia existed before the therapy): 
- Platelet nadir under 20.000/μl: 50% 
- Simultaneous occurrence of thrombocytopenia and bleeding complications: 
50% 
 
The following table shows the detailed plan for dose reduction in the presence of 
hematological toxicity in CLL (Cheson et al. 1996). 
Table 3: Plan for dose reduction 
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Drop of 
thrombocyte* or of 
Hb#(nadir) 
compared to values 
before therapy. 
 
Toxicity grad◦ 
 
Absolute neutrophil 
count$ 
 
Recommended dose 
reduction 
No change 0  No 
10% 1 = 2.000 No 
11% - 24% 2 =1.500 und <2.000 No 
25% - 49% 3 =1.000 und <1.5000 No 
50% - 74% 4 = 500 und <1.000 75% 
= 75% 5 <500 50% 
*Every drop of thrombocyte under 20.000/μl is considered as grade 4-toxicity. 
# Baseline and subsequent Hb values must be determined before administration of 
packed red blood cells. 
◦ Degrees: 1 = mild, 2 = moderate, 3 = severe, 4 = life threatening, 5 = fatal. 
$ If the absolute neutrophil counts reach less than 1.000/μl, a toxicity grade 3 is 
adopted. Changes in white blood cells or lymphocytes are not considered, because the 
decrease in white blood cell count is a therapeutic target. If the neutrophil count is less 
than 1.000/μl before therapy, the toxicity is not evaluable. 
 
2.3.4. Criteria for therapy termination 
 
The following criteria lead to discontinuation of fludarabine chemotherapy: 
- Lack of response or disease progression after 2 cycles 
- Occurrence of severe adverse effects, especially life threatening complications 
After discontinuation of therapy, no further chemotherapy is performed until the occurrence 
of an indication for therapy. 
 
2.3.5. Procedures in the observation arm 
 
Patients in cohort II and III belong to the observation arm. They are not treated with 
fludarabine, but only observed. They would be only observed until the occurrence of therapy 
indications. 
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2.3.6. Therapy for progression or relapse  
 
It is scheduled to include patients with progression or relapse in the CLL-4 study ( fludarabine 
vs. combination of fludarabine-cyclophosphamide) if they are younger than 65 years old. 
Patients over 65 years old would be included in the CLL-5 study (fludarabine vs. 
chlorambucil). 
If patients in cohort I show progression or relapse after fludarabine therapy, they should be 
further treated according to the CLL-6 protocol (therapy combination consisting of 
fludarabine, cyclophosphamide, and mitoxantrone). 
If patients reject the above mentioned therapy in different studies, they would be treated 
with fludarabine, unless they have history of no-response under fludarabine therapy.  
According to the consensus recommendations of the German Study Group, indications of 
therapy for progression or relapse are defined as follows: 
- Progression to Binet stage C or symptomatic Binet stage B 
- Progression with continuous increase of absolute lymphocyte count ≥ 100% and / or 
increase of leukocyte count > 300.000/ μl 
- Development of severe B-symptoms. 
 
 
2.4. Evaluation 
2.4.1. Definition of treatment success and disease progression 
The Assessment of treatment success and disease progression is based on the new criteria of 
“National Cancer Institute-Sponsored Working Group” (Cheson et al. 1996; Cheson et al. 
1988). The results of treatment are compared with initial status at study inclusion, not at the 
beginning of treatment. 
Complete Remission (CR) 
Following criteria must for at least 2 months be met: 
 
•  Lymph nodes < 1 cm (previous lymph nodes enlargement no more detectable), 
evaluated by clinical examination, chest x-ray, abdomen ultrasound and in case of 
doubt CT-scan 
• Normal liver and spleen sizes 
• Absence of disease related symptoms 
• Peripheral blood lymphocytes <4.000/μl 
• Peripheral blood neutrophils ≥ 1.500/μl 
• Platelets ≥ 100.000/μl 
• Hemoglobin > 11g/dl (untransfused) 
• Lymphocytes <30% in bone marrow 
 
Patients with CR, who still have a focal infiltration in the histology of the bone marrow, are 
represented as nodular partial remissions (nPR). The aim is to check the quality of remission 
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through using molecular methods. 
 
 
Partial Remission (PR) 
The definition of a partial remission requires all of the following features (if abnormal prior 
to therapy) for at least 2 months: 
• ≥ 50% decrease in peripheral blood lymphocyte count from the pretherapeutic 
staging 
• ≥ 50% reduction in lymphadenopathy   
• ≥ 50% reduction of the size of the enlargement of liver and/or spleen. 
 
As well as one or more of the remaining features: 
• ANC ≥ 1500/μl or 50% improvement over baseline 
• Platelets > 100.000/ μl or 50% improvement over baseline 
• Hemoglobin > 11.0 g/dl or 50% improvement over baseline without transfusions 
 
Progression (PD) 
Progression occurs when at least one of the following criteria is met: 
• Progression to symptomatic Binet stage B or C 
• Apparent, otherwise unexplained lymphadenopathy ≥ 100% on two consecutive tests 
at intervals of at least two weeks.* One of the lymph nodes should be given a 
minimum diameter of 2 cm. 
• Appearance of new, not otherwise explicable lymphadenopathy (at least 1 cm in 
diameter) on two consecutive tests at intervals of at least two weeks. 
• Sonographically measured increase (≥ 25%) in size of liver and / or spleen (at least one 
diameter). occurrence of an apparent, previously not detectable hepatomegaly or 
splenomegaly (confirmed by sonography). 
• Long-lasting increase of absolute lymphocyte counts ≥100% (= doubling). 
• Transformation into a highly malignant NHL (Richter's syndrome) or into a 
prolymphocytic leukemia (> 55% prolymphocytes). 
 
Stable Disease (SD) 
Stable Disease (SD) is defined as the remission status if the criteria for Complete Remission 
(CR), Partial Remission (PR), and Progression (PD) are not met. 
 
 
2.5. Statistic Analysis 
 
2.5.1. Progression Free Survival (PFS) and Overall Survival (OS) 
 
The analysis of the progression free survival and overall survival is based on the method of 
Kaplan and Meier. Survival curves are compared using the Log-Rank-Test. The level of 
significance (one-sided test) is at 5%. 
 
2.5.2. Efficacy of the Fludarabine Therapy 
 
Patients in both groups (cohort I and II) are at high risk of disease progression. But only 
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patients of cohort I are treated with fludarabine. And patients of cohort II are only observed. 
If the results of both groups, therefore, are compared, the efficacy of fludarabine could be 
good evaluated. The analysis of the response rate (occurrence of CR, PR, PD, and Stable 
Disease) is descriptive. 
 
2.5.3. Impaired Immunity 
 
The frequency of AIHA and AITP are evaluated in each study arm. Especially, the influence of 
fludarabine in impaired immunity could be evaluated by comparing the result of two groups 
(Cohort I and II). The analysis of the result is descriptive. 
 
2.5.4.  Infection 
 
The frequency, duration and spectrum of infections are evaluated in each study arm. The 
results in three different arms are compared. In addition, prognostic factors for infection are 
analyzed. The influence of fludarabine in infections could be showed through this analysis. 
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3. Results 
 
3.1. Response to treatment with Fludarabine. 
 
Table 4: Response to treatment with fludarabine. 
Response to treatment with fludarabine ( n = 72 ) 
ORR CR PR SD PD 
91,6% 
66 pts 
34,7% 
25 pts 
56,9% 
41 pts 
5,6% 
4 pts 
2,8% 
2 pts 
 
 
 
Diagram 1: Response to treatment with fludarabine 
 
 
 
The table 4 and diagram 1 show the response to treatment with fludarabine. As we see, 
patients treated with fludarabine showed good results as many studies have already showed.  
91.6% of patients reached the overall response (ORR). The partial response rate (PR, 56.9%) 
was higher than the complete response rate (34.7%). Progressive disease showed only 2.8%. 
 
The following diagram 2 shows the overall survival rate and progression free survival rate 
among all three study arms. 
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Diagram 2: PFS and OS: HR-F vs. HR-WW vs. LR 
 
 
 
PFS: 
HR-F(cohort I) vs. HR-WW(cohort II) vs. LR(cohort III) 
27.9 months vs. 15.3 months vs. 64.8 months. 
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OS :  
HR-F vs. HR-WW vs. LR 
Median not yet reached 
 
Patients in cohort III showed the best overall survival (OS) rate and progression free survival 
(PFS) rate. Although, patients in cohort I showed higher PFS rate than it in cohort II, when 
compared the overall survival rate between patients in cohort I and in cohort II, there was no 
significant difference. 
 
 
 
3.2. Impaired Immunity in Patients with CLL 
 
3.2.1. Hypogammaglobulinemia 
 
The majority of patients with CLL show hypogammaglobulinemia during the course of their 
disease. Hypogammaglobulinemia is a type of immune disorder characterized by a 
quantitative reduction of all types of gamma globulins. In general, hypogammaglobulinemia 
increases the susceptibility to infections in patients with CLL. Therefore, many patients with 
hypogammaglobuliemia frequently suffer from bacterial and viral infections. These infections 
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are the most common cause of death of patients with CLL.  
 
IgA, IgG, and IgM are analyzed in our study. As cut-off values the normal serum values have 
been used.  
 
Table 5: Low levels of immunoglobulin and infection 
 
Immunogloulin 
 
Patients(n) 
Patients with Infections 
(%) 
(Yes/No) 
 
P-value 
 
IgA (mg/dl)  
≥70 
 
<70 
441 
(88.7%) 
34,0% (150/291) ns 
56 
(11.3%) 
37,5% (21/35) 
IgG (mg/dl) 
≥600 
 
< 600 
456 
(91.6%) 
33,8% (154/302) ns 
42 
(8.4%) 
38,1% (16/26) 
IgM (mg/dl) 
≥30 
 
<30 
421 
(84.7%) 
33,7% (142/279) ns 
76 
(15.3%) 
36,8% (28/48) 
 
Through the table 5, we observed that most of patient with CLL in Binet stage A had still 
normal levels of immunoglobulins. Only 11.3% in IgA, 8.4% in IgM and 15.3% in IgM showed 
reduced levels of immunoglobulins. As known well, the severity tends to increase with the 
duration and stage of the CLL. 
 
We compared the frequency of infections in normal or high levels of immunoglobulin and in 
low levels of immunoglobulin. As we see in the table 5, the frequency of infections in low 
levels of immunoglobulin was higher than in normal or high levels of immunoglobulin. 
Namely, difference of the frequency of infections in IgA was 3.5%, 4.3% in IgG, and 3.1% in 
IgM. Even though the difference is not clearly significant, we could observe a correlation 
between low levels of IgA, IgG and IgM and the frequency of infections. In fact, if we consider 
the stage and duration of CLL, we could see the tendency of patients with low levels of 
immunoglobulin to have more frequently infections. 
 
 
3.2.2. Infections 
 
Infection is one of the most common complications of CLL. Infection can be occurred by 
immune dysfunction, and hypogammaglobulinemia, and the toxic effect of chemotherapy 
like fludarabine. Moreover, infection is well known as the most common cause of death of 
patients with CLL. 
 
We evaluated the difference of the incidence, the spectrum and the duration of infection in 
all 3 study arms. 
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3.2.2.1. Frequency of infections in different study arms. 
 
Table 6: Frequency of infections according to treatment arm. 
 Total 
(n =617) 
Cohort I 
( n = 82) 
Cohort II 
( n = 79) 
Cohort III 
( n = 456) 
Number of 
patients with any 
infections 
200 (200/617 
=32.4%) 
34 (34/82 
=41.5%) 
24 (24/79 
=30.4%) 
142 (142/456 
=30.9%) 
Number of 
patients with 
severe infections* 
18 (18/617 
=2.9%) 
5 (5/82 
 =6.1%) 
2 (2/79 = 
2.5%) 
11 (11/456 = 
2.4%) 
*Severe infection: defined as Common Toxicity Criteria (CTC) grades 3 and 4 infections 
(infection requiring intravenous antibiotic, antifungal or antiviral treatment or life 
threatening infections) 
 
 
Diagram 3: Frequency of infection 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Through this study, we aimed to find out whether fludarabine therapy could increase the 
infection rate or dysregulate the immune system. We could observe different infection rates 
among in cohort I, cohort II and cohort III. As we see in the table 6 and Diagram 3, the 
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incidence of infections in cohort I was 41.5%, in cohort II 30.4% and in cohort III 30.9%. That 
is, the incidence of infections in patients treated with fludarabine was about 10% higher than 
in patients without early treatment. The incidence of severe infections showed the same 
tendency although we could relatively seldom observe severe infections. 
 
 
3.2.2.2. Spectrum and Duration of Infections 
 
• Spectrum of Infections. 
 
Table 7: Spectrum of infections (with causative organisms) according to treatment arm 
 Total Cohort I Cohort II Cohort III P-value 
Number of 
infections 
324 
(100%) 
66 (100%) 40 (100%) 218 (100%)  
Bacterial infections 117 
(36.1%) 
25 
(37.9%) 
21 
(52.5%) 
71 
(32.6%) 
0.19 
Viral infections 129 
(39.8%) 
24 
(36.4%) 
11 
(27.5%) 
94 
(43.1%) 
0.23 
Mycotic infections 5 (1.5%) 1 (1.5%) 0 (0%) 4 (1.8%) 0.10 
Others 12 (3.7%) 5 (7.6%) 1 (2.5%) 6 (2.8%) 0.10 
Not applicable 61 
(18.8%) 
11 
(16.7%) 
7 
(17.5%) 
43 
(19.7%) 
0.15 
 
Diagram 4: Spectrum of infections 
 
 
 
The table 7 and diagram 4 show the spectrum of infections. 263 infections of total 324 
infections were analyzed. The viral (39.8%) and bacterial (36.1%) infections were the most 
common spectrums. The viral infections were more frequently observed than the bacterial 
infection. However, it showed the slight difference between both spectrums. When we see 
36%
40%
1%
4%
19%
Spectrum of Infections
bacterial infections
viral infections
mycotic infections
others
Not done
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the spectrum of infection in 3 study arms, in contrast to in cohort III, the bacterial infection 
rates in cohort I and cohort II was higher than the viral infection rate. We could seldom 
observe the mycotic infections (1.5%). 
Unfortunately, we could not analyze 18.8% of infections because causative organisms were 
not documented.  
 
• Duration of Infections. 
 
Table 8: Duration of Infections 
 Total 
 (%) 
Cohort I 
 (%) 
Cohort II 
(%) 
Cohort III 
(%) 
P-value  
(%) 
Number of infections 324 (100%) 66 (100%) 40 (100%) 218 (100%)  
 
Duration of infections 
≤ 10 days 114 (35.2%) 18 (27.0%) 13 (32.5%) 83 (38.1%) 0.19 
11 -  20 d 46 (14.2%) 12 (18.2%) 7 (17.5%) 27 (12.4%) 0.13 
21 -  30 d 30 (9.3%) 9 (13.6%) 5 (12.5%) 16 (7.3%) 0.12 
31 -  40 d 2 (0.6%) 0 (0.0%) 0 (0.0%) 2 (0.9%) 0.09 
≥ 41 d 8 (2.5%) 2 (3.0%) 1 (2.5%) 5 (2.3%) 0.10 
Not applicable 124 (38.3%) 25 (37.9%) 14 (35%) 85 (39.0%) 0.21 
 
 
Diagram 5: Duration of infections 
 
 
114 of total 200 infections (57%) ended within 10 days. With increasing duration of infections, 
the incidence of infections was reduced. However, 124 of total 324 infections (38.3%) could 
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not be analyzed. Because many cases (124 of total 324 infections (38.3%)) of infections had 
to be excluded from the statistics we could not show the result completely. But we could see 
the tendency. When we compared results of each arm, infections having long duration were 
more frequently observed in cohort I than in cohort II or in cohort III. But there was a slight 
difference. Maybe, we can hypothesize through the table 8 and diagram 5 that more patients 
with infection in cohort I had longer infection than in cohort II and cohort III.                                                                                                                                
 
 
3.2.2.3. Distribution of infection sites according to treatment arm 
 
Table 9: Distribution of infection sites according to treatment arm 
 All infections Severe infections 
 Total C. I C. II C. III P- 
value 
Total C. I C. II C. III P- 
value 
Respiratory 
tract 
20 
(23.8%) 
6 4 10 0.001 2 2 0 0 0.116 
Urinary 
tract 
3  
(3.6%) 
1 2 0 0.026 0 0 0 0  
Gastro-
intestinal 
tract 
6  
(7.1%) 
0 1 5 0.058 0 0 0 0  
Skin/soft 
tissue 
39 
(46.4%) 
11 3 25 0.156 7 5 0 2 0.033 
Fever of 
unknown 
origin 
16 
(19.0%) 
0 3 13 0.053 0 0 0 0  
Not 
applicable 
241 48 27 166 0.021 12 3 1 8 0.018 
 
Diagram 6: Distribution of infection sites 
23.80%
3.60%
7.10%
46.40%
19.00%
Distribution of infection sites
Respiratory tract
Urinary tract
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Skin/soft tissue
Fever of unknown origin
37 
 
Skin/soft tissue (46.4%) was the most common infection site. Respiratory tract followed with 
23.8%. In addition to these infection sites, we could observe infections in urinary tract and 
gastrointestinal tract. 19% of infections showed fever of unknown origin. 
 
 
3.2.2.4. Infection related Mortality 
 
Table 10: Patients with infections who died due to any reason 
 Infection 
Severe  
Infection 
death 
cause of  
death 
comment 
Cohort III Yes unknown Yes Unknown No information 
Cohort III Yes Yes Yes Unknown No information 
Cohort II Yes No Yes 
Second  
disease 
Lung cancer 
Cohort II Yes No Yes 
Second  
disease 
Inoperable central lung  
cancer 
 
During and after therapy 4 patients with the report of infections died. Two patients died of 
incurable lung cancer as secondary disease. Other two patients died of unknown cause and 
one of both had severe infection.  
Through only this table 10, we could not see the manifest relation between infection and 
mortality, even though all dead patients had at least one report of infections. 
 
 
3.2.2.5. Prognostic factors of Infections 
 
Table 11: Analysis of risk factors for infection across 3 treatment arms. 
Risk factors Patients(n) Patients with infections (%) 
(Yes/No) 
P-value 
Age (year) 
<60 
 
≥60 
 
290 
32,1% 
(93/197) 
 
0.863 
 
327 
32,7% 
(107/220) 
Sex 
Male 
 
Female 
 
365 
34,5% 
(126/239) 
 
0.187 
 
248 
29,4% 
(73/175) 
IgA (mg/dl) 
≥70 
 
<70 
 
441 
34,0% 
(150/291) 
 
0.61 
 
56 
37,5% 
(21/35) 
IgG (mg/dl) 
≥600 
 
< 600 
 
456 
33,8% 
(154/302) 
 
0.57 
 
42 
38,1% 
(16/26) 
IgM (mg/dl) 
≥30 
 
 
421 
33,7% 
(142/279) 
 
0.60 
 36,8% 
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<30 76 (28/48) 
Hemoglobin (g/dl) 
≥13 
 
<13 
 
509 
33,0% 
(168/341) 
 
0.64 
 
98 
30,6% 
(30/68) 
Serum creatinine 
(mg/dl)  
≥1.5 
 
<1.5 
 
 
10 
 
90,0% 
(9/1) 
 
<0.01 
 
553 
31,8% 
(176/377) 
Platelet count 
≥150,000 
 
<150,000 
 
 
493 
 
31,2% 
(154/339) 
 
0.18 
 
111 
37,8% 
(42/69) 
Monocyte (G/l) 
≥ 1.0 
 
< 1.0 
 
113 
35,4% 
(40/73) 
 
0.57 
 
430 
32,6% 
(140/290) 
Initial Neutrophil 
Count (G/l) 
≥2 
 
<2 
 
 
513 
 
32,7% 
(168/345) 
 
0.574 
 
40 
35,0% 
(14/26) 
LDH (U/l) 
≥250 
 
<250 
 
88 
27,3% 
(24/64) 
 
0.16 
 
464 
34,9% 
(162/302) 
Splenomegaly 
(Sono/Clinic) 
Yes 
 
No 
 
 
39 
 
43,6% 
(17/22) 
 
0.14 
 
542 
32,1% 
(174/368) 
 
We analyzed the risk factors of infections. Increased serum creatinine can be regarded as the 
best risk factors of infection in our study. Only 10 patients with CLL had more than 1.5 mg/dl 
serum creatinine. And 9 of these 10 patients had infections. That means, 90% of patients 
having more than 1.5mg/dl serum creatinine had infections, although the most patients 
(98%) had less than 1.5 mg/dl serum creatinine.  The difference of infection rate between 
patients with ≥1.5 mg/dl serum creatinine and in patients with <1.5mg/dl serum creatinine is 
58.2%.   
When we analyzed IgA, IgG, and IgM, we could observe that hypogammaglobulinemia was a 
good risk factor of infections. We can see in table 11 that infection rates in normal or high 
immunoglobulins (IgA, IgG, IgM) accounts were lower than in lower immunoglobulins 
accounts. Here we only see a statistical trend. In addition, other factors, for example 
splenomegaly, low LDH and low platelet count can be regarded as proper risk factor of 
infection.  
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3.3. Autoimmune Complications of CLL 
 
Patients with chronic lymphocytic leukemia (CLL) are at increased risk for autoimmune 
complications. Autoimmune hemolytic anemia (AIHA) and autoimmune thrombocytopenia 
(AITP) are observed in approximately 20% to 35% and 2% of patients, respectively. 
 
 
3.3.1. The incidence of AIHA  
AIHA (Autoimmune hemolytic anemia) is the most common complications of B-CLL and 
occurs in 10 – 20% of the case (Rozman et al. 1995). It is also reported that the use of 
fludarabine may trigger the occurrence of AIHA and this complication may be life- 
threatening (Tertian et al. 1996; Bastion et al. 1992; Maclean et al. 1996; Tosti et al. 1992). 
 
Hamblin et al reported that a positive direct antiglobulin test in non-progressive Binet stage 
A is significantly less likely to occur (2.9%; p<0.02) than in the other stages (13.3%). Therefore, 
the occurrence of AIHA in non-progressive stage A is lower than in other stages. 
 
The positive Coombs test is the exclusion criteria. Even though there are some reports of 
Coombs negative AIHA, it is known that up to 98 % of patients with AIHA have a positive 
direct Coombs test. Therefore, we have postulated that all patients in our study have no 
AIHA at enrollment of study. 
 
We analyzed the incidence of AIHA in three different study arms.  
We show three tables as follows: the incidence of AIHA during therapy, after therapy, and the 
total incidence of AIHA during and after therapy. 
 
The incidence of AIHA during therapy 
 
Table 12: Incidence of AIHA during therapy 
 Study Arm Total 
Cohort I Cohort II Cohort III 
AIHA 
during 
Therapy 
 
 
No 
Count of patients 85 83 487 655 
% within AIHA 
during therapy 
13.0% 12.7% 74.4% 100.0% 
% within study 
arm 
96.6% 100.0% 100.0% 99.5% 
 
 
Yes 
Count 3 0 0 3 
% within AIHA 
during therapy 
100.0% 0.0% 0.0% 100.0% 
% within study 
arm 
3.4% 0.0% 0.0% 0.5% 
 
 
Total 
Count of patients 88 83 487 658 
% within AIHA 
during therapy 
13.4% 12.6% 74.0% 100.0% 
% within study 
arm 
100.0% 100.0% 100.0% 100.0% 
 
40 
 
We analyzed the incidence of AIHA during therapy (Criteria: hemoglobin <11 g/dl and ≥ 3.5 
g/dl drop from baseline).  
As we see in the table 12, we found 3 patients with AIHA only in the cohort I arm. In other 
groups patient with AIHA was not found. AIHA occurred only 0.5% of total patients, and 3.4% 
of patients in cohort I group. 
 It can be confirmed through this result that fludarabine may trigger AIHA in patients with 
CLL. 
 
The incidence of AIHA after therapy 
 
Table 13: Incidence of AIHA after therapy 
 Study Arm Total 
Cohort I Cohort II Cohort III 
AIHA 
after 
Therapy 
 
 
No 
Count of patients 70 73 441 584 
% within AIHA 
after therapy 
12.0% 12.5% 75.5% 100.0% 
% within study 
arm 
95.9% 94.8% 98.0% 97.3% 
 
 
Yes 
Count of patients 3 4 9 16 
% within AIHA 
after therapy 
18.8% 25.0% 56.3% 100.0% 
% within study 
arm 
4.1% 5.2% 2.0% 2.7% 
 
 
Total 
Count 73 77 450 600 
% within AIHA 
after therapy 
12.2% 12.8% 75.0% 100.0% 
% within study 
arm 
100.0% 100.0% 100.0% 100.0% 
 
In the table 13, we could find patients with AIHA in all study arms: 4.1% in cohort I, 5.2% in 
cohort II, and 2.0% in cohort III. CLL is well known as the most common cause of AIHA. We 
could see slightly the difference of the incidence of AIHA between in cohort I and in cohort II.   
 
The incidence of AIHA during & after therapy 
 
Table 14: Incidence of AIHA during and after therapy 
 Study Arm Total 
Cohort I Cohort II Cohort III 
AIHA 
during/after 
Therapy 
 
 
No 
Count of patients 82 79 478 639 
% within AIHA  
during/after 
therapy 
 
12.8% 
 
12.4% 
 
74.8% 
 
100.0% 
% within study 
arm 
93.2% 95.2% 98.2% 97.1% 
 
 
Yes 
Count of patients 6 4 9 19 
% within AIHA 
during/ after 
 
31.6% 
 
21.1% 
 
47.4% 
 
100.0% 
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therapy 
% within study 
arm 
6.8% 4.8% 1.8% 2.9% 
 
 
Total 
Count 88 83 487 658 
% within AIHA 
during/after 
therapy 
 
13.4% 
 
12.6% 
 
74.0% 
 
100.0% 
% within study 
arm 
100.0% 100.0% 100.0% 100.0% 
 
We could see a slightly higher incidence of AIHA during and after therapy in cohort I than 
cohort II and III: 6.8% in cohort I, 4.8% in cohort II, and 1.8% in cohort III. And total 2.9% of 
patients in study have developed AIHA. 
 
 
3.3.2. The incidence of AITP 
AITP occurs in 2-3% of CLL patients and it occurs in early stage disease and may be a 
presenting manifestation. Initial therapy for AITP should consist of prednisone. Seventy 
percent of patients respond. Splenectomy is a reasonable second-line treatment. 
Autoimmune phenomena, largely related to blood cells, are based in the immune 
dysregulation of CLL. Longer survivals in CLL patients, more treatment regimens per patient, 
and more immunosuppression with modern treatments, allow us to predict an increasing 
incidence of autoimmune blood cell diseases in CLL (Diehl LF, Ketchum LH. 1998). 
 
The cause of autoimmune phenomena in B-CLL is unclear, although it is thought to be 
associated with disturbances in T cell subsets secondary to the B cell proliferation (Catovsky 
D. 1984). In most cases the cause of AITP is bone marrow infiltration with leukemia. Because 
of the unsatisfactory nature of platelet antibody tests, the true prevalence of AITP in CLL is 
unknown.  
 
Fludarabine has been reported to be causative in
 
the onset of autoimmune 
thrombocytopenia with CLL. Montillo et al first reported relapse of CLL-associated AITP after 
treatment with fludarabine (Montillo et al. 1994). And then Hamblin TJ reported that a total 
of 25 cases of fludarabine-associated AITP have been reported (Hamblin TJ, 2001). Contrary 
to the reports of Montillo et al and Hamblin, Dearden reported that the development of AITP 
occurred predominantly in patients who were not receiving therapy, 25% of the cases 
occurring at, or shortly after, CLL diagnosis. There was no association with use of fludarabine 
although other cases have been reported in the literature (Dearden C, 2008). Actually, there 
is no consensus about standard criteria of AITP and the association with treatment with 
fludarabine.  
 
We analyzed the incidence of AITP (Criteria: platelet count: < 100.000/µl and ≥ 50.000/µl 
drop from baseline). 
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The incidence of AITP during therapy 
 
Table 15: Incidence of AITP during therapy 
 Study Arm Total 
Cohort I Cohort II Cohort III 
AITP 
during 
Therapy 
 
 
No 
Count of 
patients 
69 83 485 637 
% within AITP  
during therapy 
10.8% 13.0% 76.1% 100.0% 
% within study 
arm 
79.3% 100.0% 100.0% 97.3% 
 
 
Yes 
Count of 
patients 
18 0 0 18 
% within AITP 
during therapy 
100.0% .0% .0% 100.0% 
% within study 
arm 
20.7% .0% .0% 2.7% 
 
 
Total 
Count of 
patients 
87 83 485 655 
% within AITP 
during therapy 
13.3% 12.7% 74.0% 100.0% 
% within study 
arm 
100.0% 100.0% 100.0% 100.0% 
 
In the table 15, the occurrence of AITP during therapy was observed in 18 patients (20.7%) 
only in cohort I.  
 
 
The incidence of AITP after Therapy 
 
 
Table 16: Incidence of AITP after therapy 
 Study Arm Total 
Cohort I Cohort II Cohort III 
AITP 
after 
Therapy 
 
 
No 
Count of 
patients 
68 74 433 575 
% within AITP 
after therapy 
11.8% 12.9% 75.3% 100.0% 
% within study 
arm 
94.4% 96.1% 96.7% 96.3% 
 
 
Yes 
Count of 
patients 
4 3 15 22 
% within AITP 
after therapy 
18.2% 13.6% 68.2% 100.0% 
% within study 
arm 
5.6% 3.9% 3.3% 3.7% 
 
 
Count of 
patients 
72 77 448 597 
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Total % within AITP 
after therapy 
12.1% 12.9% 75.0% 100.0% 
% within study 
arm 
100.0% 100.0% 100.0% 100.0% 
 
After therapy we found more occurrences of AITP in all study arms. The incidence of AITP in 
cohort I was higher than in other groups: 5.6% in cohort I, 3.9% in cohort II, and 3.3% in 
cohort III. 
 
 
The incidence of AITP during & after Therapy 
 
Table 17: Incidence of AITP during & after therapy 
 Study Arm Total 
Cohort I Cohort II Cohort III 
AITP 
during/after 
Therapy 
 
 
No 
Count of 
patients 
68 80 470 618 
% within AITP  
during/after 
therapy 
  
11.0% 
 
12.9% 
 
76.1% 
 
100.0% 
% within study 
arm 
78.2% 96.4% 96.9% 94.4% 
 
 
Yes 
Count of 
patients 
19 3 15 37 
% within AITP 
during/ after 
therapy 
51.4% 8.1% 40.5% 100.0% 
% within study 
arm 
21.8% 3.6% 3.1% 5.6% 
 
 
Total 
Count of 
patients 
87 83 485 655 
% within AITP 
during/after 
therapy 
 
13.3% 
 
12.7% 
 
74.0% 
 
100.0% 
% within study 
arm 
100.0% 100.0% 100.0% 100.0% 
 
The total incidence of AITP during and after therapy is showed in above table. 
We could observe 19 patients in cohort I (21.8%), 3 patients in cohort II (3.6%), and 15 
patients in cohort III(3.1%) who have developed AITP.  
The incidence of ITP is significantly higher in cohort I than in cohort II and III.  
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4. Discussion 
 
Before the appearance of purine analogs, such as fludarabine, cladribine, and pentostatin 
(Nipent), Chlorambucil was the standard first-line therapy for treatment of patients with CLL. 
But it has been suggested that chlorambucil might increase long-term toxicity in patients 
treated with it, when compared to patients without treatment with it.  
Comparative, randomized and non-randomized studies showed that higher chlorambucil 
doses induce a higher response rate and a longer overall survival. However, higher 
chlorambucil doses showed, as expected, higher hematological toxicity than standard doses 
(Maura et al. 2006). 
  
The appearance of purine analogs was a big step for the treatment of patients with CLL, 
because it was proved that fludarabine as single agent induced higher complete response 
rates than chlorambucil and improved patients’ quality of life. (Rai et al. 2000; Eichhorst et al. 
2003). The purine analogs now used are following: fludarabine, cladribine, and pentostatin 
(Nipent). Fludarabine of these has been most widely tested and used for treatment of 
patients with CLL. 
 
In addition, fludarabine plus cyclophosphamide combination chemotherapy resulted in 
significantly higher complete remission rate (24%) and overall response rate (94%) compared 
with fludarabine alone (7% and 83%; P<.001 and P=.001). Fludarabine plus 
cyclophosphamide treatment also resulted in longer median progression-free survival (48 vs 
20 months; P=.001) and longer treatment-free survival (37 vs 25 months; P<.001). But so far, 
no difference in median overall survival has been observed.  
Fludarabine plus cyclophosphamide combination therapy showed that this therapy caused 
significantly more thrombocytopenia and leukocytopenia compared with fludarabine alone 
but did not increase the number of severe infections (Eichhorst et al 2006). 
 
 
4.1. Response Rates 
 
We tried to evaluate the efficacy of fludarabine as a single agent in early CLL Binet stage A 
through the study. The table 4 shows that 91.6% of patients reached the overall response 
(ORR). The partial response (PR) rate was 56.9% and the complete response (CR) rate 34.7%. 
And the progression disease (PD) showed only 2.8%. When compared PFS-rate and overall 
survival rate in three study arms, patients in cohort III showed the best overall survival rate 
and progression free survival (PFS) rate. There was no difference in the overall survival rate 
between patients in cohort I and in cohort II, although patients in cohort I showed higher PFS 
rate than it in cohort II.  
 
The study of Rai et al showed that the response rate was significantly higher for fludarabine 
monotherapy than for chlorambucil. According to the study, among 170 patients treated with 
fludarbine, 20% had a complete remission, and 43% had a partial remission. Therefore, ORR 
was 63%. 
The corresponding values for 181 patients treated with chlorambucil were 4% CR and 33% PR 
(P< .001 for both comparisons). And ORR was only 37%. The median duration of remission 
and the median progression-free survival in the fludarabine group were 25 months and 20 
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months, respectively, whereas both values were 14 months in the chlorambucil group 
(P< .001 for both comparisons). The median overall survival among patients treated with 
fludarabine was 66 months, and 56 months among patients treated with chlorambucil. The 
difference between two groups was not significant. And severe infections and neutropenia 
was more frequently observed among patients treated with fludarabine than with 
chlorambucil.  
This study has tried to assess the efficacy of the fludarabine plus chlorambucil combination 
therapy. But they had to stop investigating the efficacy of combined treatment because of 
excessive rates of life-threatening toxic effects (Rai et al. 2000). 
 
The study of Eichhorst et al showed that fludarabine plus cyclophosphamide combination 
therapy in first-line treatment of younger patients with CLL resulted in higher response rates 
(complete remission rate: 24%, overall response rate: 94%) and the treatment-free survival 
(37 months) than fludarabine monotherapy (complete remission rate: 7%, overall response 
rate: 94%, treatment-free survival: 25 months). The patients were younger than 66 years and 
had predominantly advanced CLL (Eichhorst et al.2006). 
 
Our results showed higher response rates (ORR: 91.6%, CR: 34.7%), when compared our 
study with studies of Rai et al (ORR: 63%, CR: 20%) and Eichhorst et al (ORR: 83%, CR: 7%). 
We analyzed patients in Binet stage A. Therefore, patients in our study were in early stage of 
CLL. But patients in study of Rai et al were in advanced stage of CLL. Therefore, we had a 
higher response rates than both studies. 
 
Thomas et al investigated the activity of rituximab in untreated high risk, early-stage CLL. 
According to this study, the overall response rate was 90% (complete response: 19%, nodular 
partial response: 19% and partial response: 48%) (Thomas et al. 2002). 
These results showed that rituximab has significant efficacy for treatment of patient with 
early-stage CLL. But the median follow-up was only 8 months (range: 2-16 months). To 
investigate the efficacy of rituximab as a single agent more accurately, this study requires 
longer follow-up. 
 
 
4.2. Impaired Immunity and Infections. 
 
Patients with CLL show a dysregulated immune system, such as T- and B-cell dysfunction, 
hypogammaglobulinemia and autoimmune complications.  
The impaired immunity is well-known as a typical complication for patients with CLL and is 
caused by quantitative and qualitative defects in B- and T-cells. Therefore, a typical 
complication of impaired immunity is infection because of dysfunction of immune system. 
We analyzed the incidence of infections in different study arms. Through this study we aimed 
to show influence of fludarabine therapy in impaired immunity by analyzing 
hypogammaglobulinemia and infection. 
Firstly, we analyzed incidence of hypogammaglobuliemia. As we see in table 5, we could 
observe the reduction of immunoglobulin: 11.3% of patients showed low levels of IgA. 8.4% 
in IgM and 15.3% in IgM showed low levels of immunoglobulin. The most patients with Binet 
stage A presented with normal quantitative immunoglobulins and absolute neutrophils 
values. It is well-known that the severity tends to increase with the duration and stage of CLL. 
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Through the table 5, we could compare incidence of infections between the patients with 
normal or higher levels of immunoglobulin and patients with low levels of immunoglobulin, 
and patients with low levels of immunoglobulin showed slightly higher incidence of infection. 
 
Next, we observed infections of patients. As we know, infection is well known as the most 
common cause of death of patients with CLL. Through the table 6, we can see the incidence 
of infection in 3 study arms: 41.5% of patients in cohort I, 30.4% of patients in cohort II and 
30.9% of patients in cohort III. When compared the results of three study arms, we could see 
apparently higher incidence of infection in cohort I. And the incidence of infection between 
in cohort II and in cohort III almost showed no difference. If we compare the difference of 
incidence between in cohort I and in cohort II, we can better observe the influence of 
fludarabine therapy in incidence of infection. The incidence of infection showed 11.1% 
higher in cohort I than in cohort II, which means that fludarbine therapy increased the 
incidence of infection. When we observed the incidence of severe infections in three study 
arms, we could see the same results. We could see higher incidence of severe infections in 
cohort I than other two study arms, even though we could rarely observe the incidence of 
severe infections. 
We also analyzed the duration of infections, infection-related mortality and prognostic 
factors of infections. When observed the duration of infections, it was difficult to find the 
difference of results in three study arms. However, we could see through the diagram 5 that 
infections with long duration were relative frequently observed in patients of cohort I than 
in patients of other two study arms. 
In the group of patients with documented infections we observed 4 dead patients, which 
were all patients with high risk of progression stratified and randomized in cohort I. Infection 
is well-known as the main cause of death in patients with CLL. Therefore, we aimed to show 
association of death of patient with infections. One of them had a documentation of severe 
infection. However, when we observed the cause of death, lung cancer was the cause of 
death of two patients. And the other patients died of unknown cause. Therefore our study 
results can not demonstrate that the main reason for death is infection. Patients in our study 
had CLL in early Binet stage A. That means that most patients were still healthy and the 
immune system of them was not significantly weakened.  
Through analyzing the risk factors of infections (see table 11), we could find that increased 
serum creatinine can be regarded as the best risk factor of infection. There were 10 patients 
with CLL having more than 1.5 mg/dl serum creatinine. And 9 of these 10 patients had 
infections. That means, 90% of patients having more than 1.5mg/dl serum creatinine had 
infections, although the most patients (98%) had less than 1.5 mg/dl serum creatinine. The 
difference of infection rate between in patients with ≥1.5 mg/dl serum creatinine and in 
patients with <1.5mg/dl serum creatinine is 58.2%.  
In addition, hypogammaglobulinemia, splenomegaly, low LDH and low platelet count can be 
regarded as proper risk factors of infection.  
 
 
4.3. Autoimmune Complications of CLL 
 
CLL is associated with an acquired immune defect that can cause autoimmune complications, 
including autoimmune hemolytic anemia (AIHA) and autoimmune thrombocytopenia (AITP). 
We analyzed the incidence of AIHA and AITP in 3 arms. Unfortunately, there are no fixed 
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standard criteria for diagnosis of AIHA and AITP now. So we have set the criteria for diagnosis 
of AIHA and AITP as follows [AIHA: hemoglobin < 11mg/dl and ≥ 3.4 mg/dl drop from 
baseline, AITP: platelet count: < 100.000/㎕ and ≥ 50.000/㎕ drop from baseline]. 
 
AIHA 
AIHA is well-known as the most common complications of CLL. And it is repeatedly reported 
that AIHA can be triggered by fludarabine. Therefore, we analyzed the incidence of AIHA in 3 
study arms. Especially, we compared the incidence of AIHA between in cohort I and in cohort 
II. Both study arms include patients with high risk of progression. But only the patients in 
cohort I receive treatment with fludarabine. Therefore, by comparing the incidence of AIHA 
in cohort I with it in cohort II, we aimed to confirm the influence of fludarabine on the 
occurrence of AIHA. 
During therapy, we could observe 3 patients only in cohort I who developed AIHA. In other 
words, AIHA occurred 3.4% of patients in cohort I, and 0% of patients in cohort II and III. 
Through this result, it can be confirmed that fludarabine may increase the incidence of AIHA 
in patients with CLL. 
After therapy, we analyzed again the incidence of AIHA in a observational period of 24 
months. We could find 16 patients with AIHA in all 3 study arms. And the incidence of AIHA 
in cohort II (5.2%) was higher than in cohort I (4.1%) and III (2.0%). It is already well-known 
that progressive CLL is the most common cause of AIHA. 
 
The total incidence of AIHA during and after therapy is shown on the table 14. 
The total incidence of AIHA in 3 study arms is as follows: 6.8% in cohort I, 4.8% in cohort II 
and 1.8% in cohort III. 
As expected, we could observe more incidence of AIHA in cohort I than cohort II and III. And 
more occurrences of AIHA were observed in cohort I and II than in cohort III. 
  
AITP 
Approximately 2% of patients with CLL develop clinically significant autoimmune 
thrombocytopenia (AITP). There are no clear criteria for diagnosis and the platelet antibody 
tests lack sensitivity and specificity. Nevertheless, the occurrence of a rapid unexplained fall 
in platelets, in the absence of evidence of bone marrow (BM) failure or hyposplenism, 
suggest an immune origin for the thrombocytopenia. 
Early onset of ITP and refractoriness to treatment were associated with the poorest 
outcomes (Dearden. 2008) 
 
We analyzed the incidence of AITP in 3 study arms. 
During therapy we could find 18 patients with AIHA only in cohort I. After therapy we found 
more occurrences of AITP in all study arms. The incidence of AITP in cohort I was higher than 
in other two study arms: 5.6% in cohort I, 3.9% in cohort II, and 3.3% in cohort III. Totally, we 
could observe 19 patients in cohort I (21.8%), 3 patients in cohort II (3.6%), and 15 patients 
in cohort III (3.1%) who have developed AITP. The incidence of ITP is significantly higher in 
cohort I than in cohort II and III.  
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5. Conclusion 
 
Until now, with conventional therapies CLL cannot be cured. There is an increasing trend 
toward no treatment at the time of initial diagnosis. Therefore, the standard option to treat 
patients with high risk of progression in CLL Binet stage A is the “watch and wait” strategy. 
Our CLL-1 study intended to answer the question, whether administration of early and risk-
adapted fludarabine as a monotherapy in CLL Binet stage A patients with high risk of 
progression would bring an advantage for the patients. In addition, we tried to analyze the 
side-effect of the treatment with fludarabine.   
Fludarabine is the best studied purine analogue used for the treatment of CLL. The major 
side-effects are myelosuppression with neutropenia and immunosuppression and reduction 
of the T helper cells, at higher doses CNS toxicity (rarely progressive encephalopathy), 
nausea, vomiting, mucositis/stomatitis, diarrhea, anorexia and elevation of transaminases. 
We analyzed the incidence of infection, impaired immunity and autoimmune complications 
(AIHA, AITP) in all three different study arms. 
 
We could observe that the treatment with fludarabine could not prolong the overall survival 
rate in patients with high risk progression in CLL Binet stage A, although patients treated with 
fludarabine showed higher PFS rate.  
 
The incidence of infection was higher in cohort I than in cohort II & III (41.5% vs. 30.4% & 
30.9%). Furthermore, the incidence of severe infection was also higher in cohort I than other 
two arms (6.1% vs. 2.5% & 2.4%), even though we could rarely observe the incidence of 
severe infection. It was observed that the incidence of infection showed no difference 
between patients in the observation arms regardless of risk of progression (cohort II: 30.4%, 
cohort III: 30.9%). The most common spectrums were viral (39.8%) and bacterial (36.1%) 
infections, mycotic infections were rare (1.5%). Soft tissue infections, respiratory tract 
infections and FUO were the most common sites of infections. Soft tissue infections were 
significantly more observed in the cohort I arm. Among the severe infections significantly 
more respiratory tract and soft tissue infections were observed in the cohort I arm. No fatal 
infection was observed. In the analysis of risk factors of infection, serum creatinine can be 
regarded as the best risk factor in our study. In addition, IgA, IgG, IgM, splenomegaly, low 
LDH and low platelet count can be regarded as proper risk factor of infection. Our data show 
a trend for the hypothesis that the risk for infections is higher in patients treated with 
fludarabine. 
 
The autoimmune complications were observed in three study arms. The occurrence of AIHA 
during therapy was observed in 3 patients (3.4%) of only the cohort I arm. After therapy, 
patients developed AIHA were observed in all study arms; cohort I: 3 patients (4.1%), cohort 
II: 4 patients (5.2%), cohort III: 9 patients (2.0%). Total incidence of AIHA in all study arms 
were as follows; cohort I: 6 patients (6.8%), cohort II: 4 patients (4.8%), cohort III: 9 patients 
(2.0%). We could observe that patients treated with fludarabine (cohort I) showed slightly 
higher incidence of AIHA than other study arms.  
The occurrence of AITP during therapy was observed in 18 patients (20.7%) in only the 
cohort I arm. After therapy we could observe the occurrence of AIHA in all study arms; 
cohort I: 4 patients (5.6%), cohort II: 3 patients (3.9%), cohort III: 15 patients (3.3%). Total 
incidence of AITP was as follows: cohort I: 19 patients (21.8%), cohort II: 3 patients (3.6%), 
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cohort III: 15 patients (3.1%). Through this study we could observe that patients received 
fludarabine therapy (cohort I) showed significantly higher incidence of AITP.   
Our study shows a trend for the hypothesis that the risk of autoimmune complications is 
associated with the treatment with fludarabine.  
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Figure 1: 
 
 
 
CLL-1 study flow sheet 
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9. Appendix 
 
Table 18: ECOG Performance Status Scale 
ECOG Performance Status 
Score Description 
0 Asymptomatic (Fully active, able to carry on all pre-disease activities without any 
restriction) 
1 Symptomatic but completely ambulatory (Restricted in physically strenuous 
activity but ambulatory and able to carry out work of a light or sedentary nature. 
For example, light housework, office work) 
2 Symptomatic, <50% in bed during the day (Ambulatory and capable of all self care 
but unable to carry out any work activities. Up and about more than 50% 
3 Symptomatic, >50% in bed, but not bedbound (Capable of only limited selfcare, 
confined to bed or chair 50% or more of waking hours) 
4 Bedbound (Completely disabled. Cannot carry on any self-care. Totally confined to 
bed or chair) 
5 Death 
 
“ECOG” represents the “performance status” of the patients according to the criteria used by 
ECOG (Eastern Cooperative Oncology Group) (Oken et al 1982).  
 
The performance statuses were analyzed prior to the therapy in every patient. Patients with 
an ECOG-status of more than 2 would not be able to meet the inclusion criteria and 
therefore would be excluded from the study. 
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10.  Glossary of Abbreviation 
 
 
 
 
 
 
ADH Antidiuretic Hormone 
AIHA Autoimmune Hemolytic Anemia 
AITP Autoimmune Thrombocytopenia 
CLL Chronic Lymphocytic Leukemia 
CNS Central Nervous System 
CR Complete Remission 
CTC Common Toxicity Criteria 
ECOG Eastern Cooperative Oncology Group 
EORTC European Organization for Research and Treatment of Cancer 
FACS Fluorescence Activated Cell Sorting 
GCLLSG German CLL Study Group 
GITMO Italian Group for Bone Marrow Transplantation 
HR-F High Risk-Fludarabine 
HR-WW High Risk-Watch and Wait 
LDH Lactate Dehydrogenase 
LDT Lymphocyte Doubling Time 
LR Low Risk 
NCI National Cancer Institute 
NCI-WG National Cancer Institute-sponsored Working Group  
nCR Nodular Complete Remission 
NHL Non Hodgkin Lymphoma 
OS Overall Survival 
PR Partial Response 
PD Progressive Disease 
PFS Progression Free Survival 
SD Stable Disease 
SIE Intalian Society of Hematology 
SIES Italian Society of Experimental Hematology 
sTK Serum Thymidine Kinase 
W&W Watch and Wait 
WHO World Health Organization 
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